(1.16%) 5 106.89 points
(0.52%) 38 282 points
(2.14%) 15 946 points
(0.55%) $84.03
(-4.15%) $1.570
(0.16%) $2 346.20
(-0.36%) $27.26
(0.18%) $922.20
(0.35%) $0.935
(0.68%) $11.03
(0.18%) $0.801
(-0.35%) $91.85
Live Chart Being Loaded With Signals
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer...
Stats | |
---|---|
Today's Volume | 48 998.00 |
Average Volume | 18 057.00 |
Market Cap | 14.24M |
EPS | $0 ( 2023-03-23 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.320 |
ATR14 | $0.103 (21.91%) |
Volume Correlation
Celyad SA Correlation
10 Most Positive Correlations | |
---|---|
GAINL | 0.944 |
OXBR | 0.856 |
CLLS | 0.85 |
BLI | 0.84 |
CVAC | 0.827 |
SIFY | 0.824 |
AMKR | 0.819 |
XOS | 0.819 |
CTMX | 0.803 |
RAIN | 0.801 |
10 Most Negative Correlations | |
---|---|
RMRM | -0.809 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Celyad SA Correlation - Currency/Commodity
Celyad SA Financials
Annual | 2022 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-1.810 |
FY | 2022 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-1.810 |
FY | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-0.844 |
FY | 2020 |
Revenue: | $5 000.00 |
Gross Profit: | $5 000.00 (100.00 %) |
EPS: | $-1.230 |
Financial Reports:
No articles found.
Celyad SA
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators